How Does Target Lesion Selection Affect RECIST? A Computer Simulation Study
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
How Does Target Lesion Selection Affect RECIST? A Computer Simulation Study
Authors
Keywords
-
Journal
INVESTIGATIVE RADIOLOGY
Volume -, Issue -, Pages -
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2023-11-04
DOI
10.1097/rli.0000000000001045
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Incorporating lesion-to-lesion heterogeneity into early oncology decision making
- (2023) Rukmini Kumar et al. Frontiers in Immunology
- Imaging endpoints for clinical trial use: a RECIST perspective
- (2022) Saskia Litière et al. Journal for ImmunoTherapy of Cancer
- Development of a Prognostic AI-Monitor for Metastatic Urothelial Cancer Patients Receiving Immunotherapy
- (2021) Stefano Trebeschi et al. Frontiers in Oncology
- RECIST 1.1 and lesion selection: How to deal with ambiguity at baseline?
- (2021) Antoine Iannessi et al. Insights into Imaging
- Not all cancers are created equal: Tissue specificity in cancer genes and pathways
- (2020) Joy J. Bianchi et al. CURRENT OPINION IN CELL BIOLOGY
- Tumor Segmentation and Feature Extraction from Whole-Body FDG-PET/CT Using Cascaded 2D and 3D Convolutional Neural Networks
- (2020) Skander Jemaa et al. JOURNAL OF DIGITAL IMAGING
- Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
- (2019) Meihua Wang et al. Journal for ImmunoTherapy of Cancer
- Predicting Response to Cancer Immunotherapy using Non-invasive Radiomic Biomarkers
- (2019) S Trebeschi et al. ANNALS OF ONCOLOGY
- From waterfall plots to spaghetti plots in early oncology clinical development
- (2019) Francois Mercier et al. PHARMACEUTICAL STATISTICS
- RECIST Needs Revision: A Wake-up Call for Radiologists
- (2019) Christiane K. Kuhl RADIOLOGY
- Components of Radiologic Progressive Disease Defined by RECIST 1.1 in Patients with Metastatic Clear Cell Renal Cell Carcinoma
- (2019) Heidi J. Coy et al. RADIOLOGY
- Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
- (2019) Li-Chun Lu et al. Liver Cancer
- Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials
- (2018) Sirisha L. Mushti et al. CLINICAL CANCER RESEARCH
- Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib
- (2018) Francesco Tovoli et al. EUROPEAN RADIOLOGY
- Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)
- (2018) Sabine Schmid et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Discrepancies of assessments in a RECIST 1.1 phase II clinical trial – association between adjudication rate and variability in images and tumors selection
- (2018) Hubert Beaumont et al. CANCER IMAGING
- Validity of RECIST Version 1.1 for Response Assessment in Metastatic Cancer: A Prospective, Multireader Study
- (2018) Christiane K. Kuhl et al. RADIOLOGY
- Predicting clinical outcomes in chordoma patients receiving immunotherapy: a comparison between volumetric segmentation and RECIST
- (2016) Kathleen E. Fenerty et al. BMC CANCER
- Observer variability in RECIST-based tumour burden measurements: a meta-analysis
- (2016) Soon Ho Yoon et al. EUROPEAN JOURNAL OF CANCER
- Comparison of CT volumetric measurement with RECIST response in patients with lung cancer
- (2016) S.A. Hayes et al. EUROPEAN JOURNAL OF RADIOLOGY
- Pitfalls in RECIST Data Extraction for Clinical Trials
- (2015) Richard G. Abramson et al. ACADEMIC RADIOLOGY
- Volume-based Response Evaluation with Consensual Lesion Selection
- (2015) Estanislao Oubel et al. ACADEMIC RADIOLOGY
- Target Lesion Selection
- (2014) Sebastian Keil et al. INVESTIGATIVE RADIOLOGY
- Missing Data and Measurement Variability in Assessing Progression-Free Survival Endpoint in Randomized Clinical Trials
- (2013) R. Sridhara et al. CLINICAL CANCER RESEARCH
- The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement
- (2013) L. C. Villaruz et al. CLINICAL CANCER RESEARCH
- Volumetric response classification in metastatic solid tumors on MSCT: Initial results in a whole-body setting
- (2013) A.M. Wulff et al. EUROPEAN JOURNAL OF RADIOLOGY
- Observer variability in a phase II trial – assessing consistency in RECIST application
- (2012) Kristin Skougaard et al. ACTA ONCOLOGICA
- Change in Tumor Size by RECIST Correlates Linearly With Overall Survival in Phase I Oncology Studies
- (2012) Rajul K. Jain et al. JOURNAL OF CLINICAL ONCOLOGY
- The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee
- (2010) L. Seymour et al. CLINICAL CANCER RESEARCH
- A simulation study to evaluate the impact of the number of lesions measured on response assessment
- (2008) Chaya S. Moskowitz et al. EUROPEAN JOURNAL OF CANCER
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More